Compare ROMA & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | TECH |
|---|---|---|
| Founded | 2018 | 1976 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.1M | 11.4B |
| IPO Year | 2022 | 1995 |
| Metric | ROMA | TECH |
|---|---|---|
| Price | $8.80 | $72.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $70.50 |
| AVG Volume (30 Days) | 2.7K | ★ 2.9M |
| Earning Date | 07-31-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.44% |
| EPS Growth | N/A | ★ 152.17 |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $1,215,039,000.00 |
| Revenue This Year | N/A | $4.35 |
| Revenue Next Year | N/A | $10.04 |
| P/E Ratio | ★ N/A | $62.41 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.16 | $43.20 |
| 52 Week High | $11.77 | $72.69 |
| Indicator | ROMA | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 61.21 |
| Support Level | $8.15 | $72.11 |
| Resistance Level | $9.73 | $72.66 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 52.63 | 82.47 |
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.